Evidence map›Paper›PMID 30192380›Full record

ArticleActa neurologica Scandinavica2019

Glucose metabolism in the brain in LMNB1-related autosomal dominant leukodystrophy.

Johannes Finnsson, Mark Lubberink, Irina Savitcheva, David Fällmar, Atle Melberg, Eva Kumlien, Raili Raininko

Open access · hybridAbstract read
In one paragraph

Article in Acta neurologica Scandinavica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Johannes FinnssonRadiology, Uppsala University, Uppsala, Sweden.
Mark LubberinkNuclear Medicine and PET, Uppsala University, Uppsala, Sweden.
Irina SavitchevaNuclear Medicine and PET, Uppsala University, Uppsala, Sweden.
David FällmarRadiology, Uppsala University, Uppsala, Sweden.
Atle MelbergNeuroscience, Neurology, Uppsala University, Uppsala, Sweden.
Eva KumlienNeuroscience, Neurology, Uppsala University, Uppsala, Sweden.
Raili RaininkoRadiology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-6897-7593
Uppsala University · SE

Funding

Hedberg FoundationLändell FoundationSelander FoundationSwedish Medical Research Council 73X-13158Swedish Medical Research Council K2013-66X-10829-20-3
6 · The paper itself

Abstract

objectiveLMNB1-related autosomal dominant leukodystrophy is caused by an overexpression of the protein lamin B1, usually due to a duplication of the LMNB1 gene. Symptoms start in 5

methodsWe examined 8 patients, aged 48-64 years, in varying stages of clinical symptomatology. Two patients were investigated with quantitative PET on clinical indications after which six more patients were recruited. Absolute glucose metabolism was analyzed with the PVElab software in 6 patients and 18 healthy controls. A semiquantitative analysis using the CortexID software was performed in seven investigations, relating local metabolism levels to global glucose metabolism.

resultsThe clinical quantitative PET revealed low global glucose metabolism, with the most marked reduction in the cerebellum. In the PVElab analysis, patients presented low mean glucose metabolism in the cerebellum, brainstem and global grey matter. In the semiquantitative analysis, 2 patients showed a decreased metabolism in the cerebellum and 4 patients a relatively higher metabolism in parts of the temporal lobes. Since none of the patients showed an increased metabolism in the quantitative analysis, we interpret these increases as "pseudo-increases" related to a globally reduced metabolism.

conclusionsGlobal reduction of grey matter glucose metabolism in this white matter disease most likely depends on a combination of cortical afferent dysfunction and, in later stages, neuronal loss. The lowest metabolism in the cerebellum is consistent with histopathological findings and prominent cerebellar symptoms.

Indexed as

Positron-Emission TomographyCerebellumFemaleFluorodeoxyglucose F18HumansLamin Type BMaleMiddle AgedPelizaeus-Merzbacher DiseaseRadiopharmaceuticalsFluorodeoxyglucose F18Lamin Type BRadiopharmaceuticals18F-fluorodeoxyglucoseadult-onset leukodystrophyautosomal dominant leukodystrophyglucose metabolismpositron emission tomography

Identifiers

PMID30192380
PMCPMC6585974
OpenAlexW2890815152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.